These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 29364197)

  • 1. Semaglutide (Ozempic)--another injectable GLP-1 receptor agonist for type 2 diabetes.
    Med Lett Drugs Ther; 2018 Jan; 60(1539):19-21. PubMed ID: 29364197
    [No Abstract]   [Full Text] [Related]  

  • 2. Glucagon-like peptide-1 receptor agonists and cardiovascular disease: from LEADER to EXSCEL.
    Torekov SS
    Cardiovasc Res; 2018 Aug; 114(10):e70-e71. PubMed ID: 30052921
    [No Abstract]   [Full Text] [Related]  

  • 3. Semaglutide: First Global Approval.
    Dhillon S
    Drugs; 2018 Feb; 78(2):275-284. PubMed ID: 29363040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Semaglutide injection for the treatment of adults with type 2 diabetes.
    Chudleigh RA; Bain SC
    Expert Rev Clin Pharmacol; 2020 Jul; 13(7):675-684. PubMed ID: 32476529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of injectable semaglutide for type 2 diabetes.
    Peter R; Bain SC
    Expert Opin Drug Saf; 2020 Jul; 19(7):785-798. PubMed ID: 32428416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral GLP-1 analogue: perspectives and impact on atherosclerosis in type 2 diabetic patients.
    Saraiva JFK; Franco D
    Cardiovasc Diabetol; 2021 Dec; 20(1):235. PubMed ID: 34911560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Semaglutide once-weekly: improved efficacy with a new safety warning.
    Coon SA; Crannage EF; Kerwin LC; Guyton JE
    Expert Rev Clin Pharmacol; 2018 Nov; 11(11):1061-1072. PubMed ID: 30296182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.
    Wright EE; Aroda VR
    Postgrad Med; 2020 Nov; 132(sup2):26-36. PubMed ID: 32815423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?
    Doggrell SA
    Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):371-377. PubMed ID: 29439603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low incidence of anti-drug antibodies in patients with type 2 diabetes treated with once-weekly glucagon-like peptide-1 receptor agonist dulaglutide.
    Milicevic Z; Anglin G; Harper K; Konrad RJ; Skrivanek Z; Glaesner W; Karanikas CA; Mace K
    Diabetes Obes Metab; 2016 May; 18(5):533-6. PubMed ID: 26847401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Glucagon-Like Peptide-1 Receptor Agonist, Semaglutide, for the Treatment of Nonalcoholic Steatohepatitis.
    Dichtel LE
    Hepatology; 2021 Oct; 74(4):2290-2292. PubMed ID: 33960005
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacokinetics and Clinical Implications of Semaglutide: A New Glucagon-Like Peptide (GLP)-1 Receptor Agonist.
    Hall S; Isaacs D; Clements JN
    Clin Pharmacokinet; 2018 Dec; 57(12):1529-1538. PubMed ID: 29915923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes.
    Andersen A; Knop FK; Vilsbøll T
    Drugs; 2021 Jun; 81(9):1003-1030. PubMed ID: 33964002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral semaglutide for the treatment of type 2 diabetes.
    Hedrington MS; Davis SN
    Expert Opin Pharmacother; 2019 Feb; 20(2):133-141. PubMed ID: 30499733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD-4 substudy.
    Jendle J; Testa MA; Martin S; Jiang H; Milicevic Z
    Diabetes Obes Metab; 2016 Oct; 18(10):999-1005. PubMed ID: 27279266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In brief: GI effects of GLP-1 receptor agonists.
    Med Lett Drugs Ther; 2023 Nov; 65(1690):191-192. PubMed ID: 37983121
    [No Abstract]   [Full Text] [Related]  

  • 17. Oral Semaglutide: Balancing Promising Therapeutics with Adverse Effects and Access Barriers.
    Gunning K
    J Manag Care Spec Pharm; 2020 Sep; 26(9):1077-1079. PubMed ID: 32857647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
    Ferdinand KC; Botros FT; Atisso CM; Sager PT
    Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral Semaglutide: First-in-Class Oral GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes Mellitus.
    Cowart K
    Ann Pharmacother; 2020 May; 54(5):478-485. PubMed ID: 31744308
    [No Abstract]   [Full Text] [Related]  

  • 20. Acute effects of the glucagon-like peptide-1 receptor agonist, exenatide, on blood pressure and heart rate responses to intraduodenal glucose infusion in type 2 diabetes.
    Thazhath SS; Marathe CS; Wu T; Chang J; Khoo J; Kuo P; Checklin HL; Bound MJ; Rigda RS; Horowitz M; Jones KL; Rayner CK
    Diab Vasc Dis Res; 2017 Jan; 14(1):59-63. PubMed ID: 27941058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.